Accepted Abstracts
Aaron Skiles
Nurse Practitioner
University of New Mexico
CLOSING THE GAP: IMPLEMENTING HEPATITIS C REFLEX TESTING WITHIN THE UNIVERSITY OF NEW MEXICO HEALTH SYSTEM
Cindy Xu
Associate Director, Medical Communications
Boston Pharmaceuticals
ONCE-MONTHLY EFIMOSFERMIN ALFA (BOS-580) IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS WITH F2/F3 FIBROSIS: RESULTS FROM A 24 WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 TRIAL
Ellie Manca
Principal Scientific Communications Manager
Red Nucleus
Long-Term Efficacy and Safety of Open-Label Seladelpar Treatment in Patients With Primary Biliary Cholangitis: Pooled Interim Results for up to 3 Years From the ASSURE Study
Joel Gay
Product Manager
E-Scopics
2D measurements of liver stiffness and quantitative ultrasound parameters with Hepatoscope provide high repeatability and good correlation with FibroScan
Julie Dubourg
Executive Director, Scientific Presentations & Innovations
Madrigal Pharmaceuticals
Use of non-invasive tests to diagnose and follow MASH with liver fibrosis patients treated with resmetirom
Julie Dubourg
Executive Director, Scientific Presentations & Innovations
Madrigal Pharmaceuticals
Baseline characteristics in well-compensated MASH cirrhosis patients diagnosed with or without a liver biopsy in MAESTRO-NASH-OUTCOMES, a clinical outcome Phase 3 study assessing the effect of resmetirom in well-compensated MASH cirrhosis
Rida Nadeem, MD
Medical Provider
Arizona Liver Health
Performance of Noninvasive Tests in Identifying Appropriate Patients for Resmetirom Treatment: Real World Data from Four Tertiary Care Centers
Rida Nadeem, MD
Medical Provider
Arizona Liver Health
Routine Cholestasis Genetic Testing in Patients with Intrahepatic Cholestasis of Pregnancy Reveals High Prevalence of Genetic Variants of Bile Acid Transport Defects
Rida Nadeem, MD
Medical Provider
Arizona Liver Health